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Abstract
It has been demonstrated for some cancers that the frequency of somatic oncogenic mutations may vary in ancestral
populations. To determine whether key driver alterations might occur at different frequencies in colorectal cancer, we
applied a high-throughput genotyping platform (OncoMap) to query 385 mutations across 33 known cancer genes in
colorectal cancer DNA from 83 Asian, 149 Black and 195 White patients. We found that Asian patients had fewer
canonical oncogenic mutations in the genes tested (60% vs Black 79% (P = 0.011) and White 77% (P = 0.015)), and
that BRAF mutations occurred at a higher frequency in White patients (17% vs Asian 4% (P = 0.004) and Black 7%
(P = 0.014)). These results suggest that the use of genomic approaches to elucidate the different ancestral
determinants harbored by patient populations may help to more precisely and effectively treat colorectal cancer.
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Introduction
It is well established that cancer is a genomic disease and
many molecular and genetic alterations are well characterized.
For example, somatic mutations in lung cancer [1],
amplifications in breast cancer [2], and fusions in acute myeloid
leukemia [3] are well known for their roles in both tumor biology
and clinical behavior and outcome. We and others have
previously shown that the frequency of somatic oncogenic
mutations can vary across distinct ancestral populations. In
non-small cell lung cancer (NSCLC), mutations in epidermal
growth factor receptor (EGFR) are more prevalent in Asian
patients compared to European-derived populations (8%
versus 30%, P < 0.001). These mutations are also found more
commonly in females and non-smokers [1,4]. Conversely,
serine threonine kinase 11 (STK11) mutations (point mutations
and deletions) are found in 17% of White NSCLC patients [5,6]
but at much lower frequency in those from Asian patients.
These observations raise the possibility that tumors from
different ancestral groups may harbor distinct patterns of driver
genetic alterations. Given that tumor somatic mutations can be
both driver events and targets for effective pharmacological
inhibition, knowledge of the associated ancestral determinants
may have important implications for studies of both cancer
health disparities and precision cancer medicine.
Colorectal cancer is the second leading cause of cancer
death in the United States. As with several cancer types,
colorectal cancer shows significant variation in incidence and
mortality rates across Asian, Black and White populations.
Blacks have the highest mortality rate (49.6 per 100,000) and
Asians have the lowest (22.7 per 100,000) (US, SEER
2005-2009). Disparities in cancer outcomes between patients
from different ancestral backgrounds have been demonstrated
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for many cancers, yet the mechanisms driving these disparities
have not been clearly elucidated.
In the US, rates of incidence and mortality in colorectal
cancer have been steadily declining due to increases in
screening [7] with the largest declines for Whites and the
smallest for Blacks. While variance in health care access and
treatment patterns may play important roles, many cancers still
exhibit differences even after accounting for these factors. For
example, a 2004 study [8] found that Black patients were 1.67
times more likely to die of colorectal cancer at 5 years post-
treatment than White patients.
In Korea, where incidence is still lower than in the US, the
picture is complex with increasing rates of both incidence and
survival [9]. Looking at global statistics, the rates of colorectal
cancer have been increasing dramatically in many Asian
countries with some experiencing a 2-4-fold increase in
incidence of colorectal cancer, and some countries
approaching rates of incidence similar to Western countries
[10,11,12]. These increases in incidence are generally
considered to result from the adoption of a more Western diet
[10,12].
The overall 5-year survival rate for colorectal cancer is 64%
in the U.S. (US, SEER 2005-2009). The range of stage specific
rates is wide. Stage 1 tumors, which have grown into the colon
but not extended outside of it, have an average 5-year survival
of 89%. In contrast, those patients with distant metastasis have
an average 5-year survival of 11%. Standard treatment for
colorectal cancer consists of surgical resection for lower stage
disease, and some combination of surgery, chemotherapy, and
radiation for later stage. Refractory disease with distant
metastasis, if EGFR expressing and KRAS wild type, can be
treated with anti-EGFR monoclonal antibodies [13]. KRAS
mutations at codons 12 and 13 are currently significant
predictors of resistance to anti-EGFR monoclonal antibodies,
and are of clinical utility in screening patients with metastatic
disease to appropriate therapy [13].
To begin to assess the extent to which prevalent driver
somatic mutations might vary with colorectal cancer patient
ancestry [14,15], we conducted a systematic interrogation of
385 mutations in 33 known cancer genes in colorectal
adenocarcinoma DNA from 427 patients including 83 Asian,
149 Black and 195 White patients by self-reported ancestry.
Materials and Methods
Patients and Tumor Specimen Collection
Our work has been reviewed by the Dana-Farber Cancer
Institute Internal Review Board (DFCI IRB). We requested and
were granted an exemption from DFCI IRB review as all
specimens in the study were de-identified and anonymized.
We analyzed 427 tissue specimens (426 paraffin embedded
and 1 fresh frozen) from patients with colorectal cancer. The
anonymized tumor specimens were obtained from the
Cooperative Human Tissue Network (CHTN), the Pathology
Specimen Locator of Dana Farber/Harvard Cancer Center (DF/
HCC), the University of Tennessee Health Science Center
(UTHSC) and Asan Medical Center. DFCI IRB exemption was
obtained for all samples. Limited pathology information was
included for each specimen with race as a requirement and
most frequently including gender, age, stage, location, and
node or metastasis status.
For all specimens, tissue was sectioned and hematoxylin
and eosin (H&E)-stained slides were obtained. Tumor-enriched
areas were identified and core punches were taken from the
corresponding region. Required tumor content was 70%.
Accompanying biopsy diagnoses (obtained from CHTN, DF/
HCC, UTHSC or Asan) were confirmed by independent
histopathological review. DNA was extracted from FFPE cores
using a QiaCube with the Qiagen QIAamp DNA FFPE Tissue
Kit and from frozen specimens using either the Qiagen QIAamp
or the Qiagen DNeasy kit according to the manufacturer’s
directions.
OncoMap genotyping
OncoMap (version 3) is a mass-spectrometric genotyping
platform that assays for 385 mutations in 33 cancer genes
listed in Table 1. Selection of cancer gene mutations for assay
design and mass spectrometric genotyping were performed as
previously described [14,15].
DNA quality was evaluated by quantification using Quant-
iT™ Pico Green® dsDNAassay Kit (Invitrogen) per
manufacturer’s protocol. 100ng genomic DNA was subjected to
whole genome amplification (WGA) using either the Sigma-
Aldrich GenomePlex Complete Whole Genome Amplification
Kit for fresh frozen or the Qiagen RepliG Mini Kit for FFPE.
IPLEX chemistry was used to generate a list of candidate
mutations. Unamplified genomic DNA was used to validate all
candidate mutations using a second (hME) chemistry. All
methods were performed as previously described [14].
Statistical analysis
Statistical significance was ascertained with a pair-wise
comparison using a two-tailed Fisher’s Exact Test with a
Bonferroni correction for multiple comparisons and a cut-off of
less than 0.05.
Results
Patient characteristics
Colorectal cancer DNA from 83 Asian, 149 Black and 195
White patients (Table 2) was analyzed using the OncoMap
platform The average patient age in our cohort was 65 years
(Asian, 63; Black, 62; White, 68) and there were more women
than men (224 vs 197). Ancestry was determined by self-
reporting. In our cohort we found colorectal cancers to be most
frequently located in the proximal colon (49%), and more
commonly Stage 3 (55%). Proximal colorectal cancers were
more common in White patients compared to Black (P = 0.009)
and Asian (P = 3.69E-07) patients. Distal cancers were most
common in Asians (P = 0.005 compared to Whites). Distal
cancers were more common in females (P = 0.007), whereas
proximal cancer was more common in males (P = 0.019). The
Asian cohort had significantly more stage I and II disease
compared to both Black (stage I, P = 0.002, stage II, P = 0.01)
and White (stage I, P = 3.08E-06, stage II, P = 3.37-05)
BRAF Mutations in Colorectal Cancer
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patients. White patients had more stage IV disease compared
to Asians in this cohort (P = 0.004). Looking at the overall
average staging for all groups, we found Whites to have the
highest average stage of disease and Asians the lowest (Asian,
2.41; Black, 2.89; White, 3.09).
Cancer gene mutations in colorectal cancer
Using OncoMap, we identified 514 mutations in 427
colorectal cancer specimens (Figure 1). We found 84 mutations
in 83 tumors from Asian patients, 177 mutations in tumors from
149 Black patients and 253 mutations in 195 tumors from
White patients. 318 tumors (74%) harbored at least one
mutation. Of the tumors with mutations, 173 (40%) had single
mutations and 145 (34%) had more than one mutation. Seven
samples harbored 4 or more mutations. Mutations in APC
(18%), BRAF (11%), KRAS (46%), PIK3CA (18%) and TP53
(17%) were found most frequently (Table 3). We found the
mutation rates of common oncogenes to be at frequencies
similar to those previously reported for colorectal cancer [16].
Overall, fewer tumors from Asian patients (60%) harbored
one or more mutations queried by OncoMap, when compared
to both Black patients (79%, P = 0.011) and White patients
(77%, P = 0.015). Single mutations were found in 31% of
tumors from Asians, 47% from Blacks and 39% from Whites,
and multiple mutations in 29%, 32% and 38% respectively.
In colorectal cancers from White patients, we identified
significantly more mutations in BRAF (17%) than in either the
Asian (4%, P = 0.004) or Black (7%, P = 0.014) cohorts (Table
4). This was largely driven by a preponderance of BRAF V600
mutations in the White cohort. We found BRAF mutations to be
more common in women, in older patients, and in the proximal
colon, consistent with other reports [17,18,19]. Patients with
BRAF mutant tumors had an average age of 72, compared to
the average age of 65 for the entire cohort, and the cancer was
located more commonly in the proximal colon (65% compared
Table 1. OncoMapV3.
Gene Mutations
ABL1 14
AKT1 1
AKT2 2
APC 12
BRAF 43
CDK4 1
CDKN2A 10
CSF1R 6
CTNNB1 31
EGFR 44
ERBB2 6
FGFR1 2
FGFR2 6
FGFR3 8
FLT3 8
HRAS 12
JAK2 1
JAK3 3
KIT 25
KRAS 22
MET 6
MLH1 1
MYC 6
NRAS 19
PDGFRA 17
PIK3CA 14
PTEN 14
RB1 11
RET 13
SRC 1
STK11 12
TP53 7
VHL 7
33 385
doi: 10.1371/journal.pone.0074950.t001
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with 49% for complete cohort). Patients with BRAF mutant
tumors were largely Stages III and IV. A higher frequency of
KRAS mutations was observed in tumors from Black patients
(Asian, 39%; Black, 53%; White, 44%) driven specifically by a
prevalence of KRAS G12D mutations (Figure 2); however, this
did not reach statistical significance.
Six tumors harbored more than one mutation in the
RAS/RAF family (KRAS, NRAS, HRAS and BRAF), with all of
them having at least one KRAS mutation (Figure 2). Of these,
two tumors (1 from an Asian patient, 1 from a Black patient)
had mutations in both KRAS G12D and G13D, which have
been previously observed [19]. There were 2 instances of
KRAS A146T, each of which co-occurred with a G12 mutation.
KRAS A146T mutations have been seen in both colorectal
cancers and colonic adenomas [20], and were associated with
a more favorable outcome. Furthermore, some A146T
mutations have been associated with copy number
amplification of the KRAS locus.
We found 3 instances of co-occurring BRAF and KRAS
mutations, all in tumors from White patients that harbored 4 or
more mutations. Co-occurring were BRAF V600E and KRAS
G13D, BRAF V600M and KRAS G12V, and BRAF G469V with
both KRAS A146T and KRAS G13D. While rare, co-
occurrences have been reported [19,21], and may represent
different populations of cells within the tumor. An evaluation of
the KRAS and BRAF allele spectral peak heights in the raw
genotyping data shows that in one case, the mutant allele
fractions of the genes were different, indicating that these may
not be present at the same frequency in the specimen.
We identified APC mutations in 14% of tumors from Asian
patients, 17% from Black patients and 19% from White
patients. APC mutations, as expected for early events in
colorectal cancer tumorigenesis, primarily co-occur with other
mutations, most commonly with KRAS, PIK3CA and/or TP53.
Because APC is a large tumor suppressor gene and OncoMap
only assays for known recurrent variants, the number of
mutations identified by genotyping likely under-represents the
true prevalence of APC mutations in these cohorts.
PIK3CA mutations nearly always co-occurred with other
mutations (92% of cases) with the most common partners
found to be RAS/RAF family members (KRAS, NRAS and
BRAF). PIK3CA mutations tend to cluster in exons 9 and 20
with exon 20 kinase domain mutations more common in breast
cancer [22] and exon 9 helical domain mutations more
common in colorectal cancer. As expected, we saw a
predominance of helical domain mutations in our cohorts
(Asian, 57%; Black, 59%; White, 65%). A few tumors harbored
two distinct PIK3CA mutations; in one instance R88Q and
C420R (p85 and C2 domains), and in another C420R and
H1047R (C2 and kinase domains). A third sample (Asian) also
had two helical domain PIK3CA mutations (E542K and E545K)
along with a KRAS and a TP53 mutation. While double PIK3CA
mutants have been previously reported [22], their significance
is unclear.
Discussion
Using the OncoMap platform, we assayed for 385 known and
clinically relevant somatic mutations in colorectal cancers from
427 Asian, Black and White patients to evaluate possible
differences in the frequency of somatic mutations in colorectal
cancer. In our study we found the mutation rate for cancers
from Asians to be significantly lower than either the Black or
White cohort. We found significant differences in the frequency
of BRAF mutations with BRAF V600E mutations occurring
most frequently in White patients. We find BRAF mutations to
be more common in cancers from White patients, women, older
patients, and in the proximal colon consistent with other reports
[23]. In addition, while not significant using the more stringent
criteria (Bonferroni correction), we found an enrichment of
KRAS mutations in the Black cohort.
While the differences in BRAF mutation frequency between
White, Black and Asian cohorts in colorectal cancer have not
Table 2. Patient characteristics.
  Asian Black White Total
Gender Female 35 87 102 224
 Male 47 59 91 197
 unknown 1 3 2 6
  83 149 195 427
Age (mean) Female 62 (33-87) 62 (30-90) 68 (36-90) 65 (30-90)
 Male 64 (43-84) 62 (26-87) 66 (22-91) 64 (22-91)
Stage Stage-I 11 (13%) 3 (2%)  14 (3%)
 Stage-II 28 (34) 26 (17%) 21 (11%) 75 (18%)
 Stage-III 36 (43%) 87 (58%) 113 (58%) 236 (55%)
 Stage-IV 4 (5%) 19 (13%) 38 (19%) 60 (14%)
 unknown 4 (5%) 15 (10%) 23 (12%) 42 (10%)
Location distal 33 (39%) 37 (25%) 41 (21%) 111 (26%)
 proximal 22 (27%) 67 (45%) 119 (61%) 208 (49%)
 rectal 25 (30%) 25 (17%) 19 (10%) 69 (16%)
 unspecified 3 (4%) 20 (13%) 16 (8%) 39 (9%)
doi: 10.1371/journal.pone.0074950.t002
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Figure 1.  Mutation spectrum by tumor and gene.  A summary chart of all mutations in each group displays genes across in rows
and patient tumors down in columns. The bottom row of each represents the total number of mutations per tumor as a heat map
(0-5 mutations). Chart A displays Asian patients, chart B, Black patients and chart C, White patients. Chart D displays the
distribution of all mutations for each cohort.
doi: 10.1371/journal.pone.0074950.g001
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been previously reported, differences between other population
groups have been noted. For example, in a recent study,
Rozek et al [18] found the BRAF V600E mutation to be more
common in persons of Ashkenazi Jewish descent and less
common in those of Arab descent. Furthermore, English et al
[24] found Australians of Anglo-Celtic descent to have a higher
incidence of colorectal cancer and significantly more BRAF
V600E mutations than those of Southern European descent.
Table 3. Gene mutations per patient population.
Genes Asian (83) % Black (149) % White (195) % Total (427) %
AKT1     2 1% 2 0.5%
APC 12 14% 26 17% 37 19% 75 17.6%
BRAF 3 4% 10 7% 33 17% 46 10.8%
CTNNB1 2 2% 2 1% 3 2% 7 1.6%
EGFR     1 1% 1 0.2%
IDH1   1 1%  0% 1 0.2%
KRAS 32 39% 79 53% 85 44% 196 45.9%
MAP2K1   2 1%  0% 2 0.5%
MYC   1 1%  0% 1 0.2%
NRAS 3 4% 1 1% 7 4% 11 2.6%
PIK3CA 13 16% 28 19% 35 18% 76 17.8%
PTEN   3 2% 5 3% 8 1.9%
RB1     2 1% 2 0.5%
RET   1 1%  0% 1 0.2%
TP53 17 20% 20 13% 36 18% 73 17.1%
no mutation* 33 40% 32 21% 44 23% 109 26%
* No mutations were identified using the assays included in OncoMap
doi: 10.1371/journal.pone.0074950.t003
Table 4. Patient characteristics for wild type and mutant BRAF.
Features  wt-BRAF m-BRAF Total
Age at diagnosis (mean, st dev) 64.7 13.9 72.3 11.2 65.5 13.9
Gender        
 Female 194 51% 30 65% 224 52%
 Male 182 48% 15 33% 197 46%
 unknown 5 1% 1 2% 6 1%
  381 100% 46 100% 427 100%
Race        
 Asian 80 21% 3 5% 83 19%
 Black 139 36% 10 22% 149 35%
 White 163 43% 33 73% 195 46%
  381 100% 46 100% 427 100%
Stage        
 I 14 4% 0 0% 14 3%
 II 73 19% 2 5% 75 18%
 III 208 55% 28 65% 236 55%
 IV 51 13% 9 21% 60 14%
 unknown 38 10% 4 9% 42 10%
  384 101% 43 100% 427 100%
Location        
 Distal 102 34% 9 21% 111 26%
 Proximal 180 60% 28 65% 208 49%
 Rectal 66 22% 3 7% 69 16%
 Colon, unspecified 36 12% 3 7% 39 9%
  384 127% 43 100% 427 100%
doi: 10.1371/journal.pone.0074950.t004
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These findings demonstrate again that the frequency of
important oncogenic mutations can vary in populations of
different ancestral backgrounds. Whether and to what degree
these variants have an impact on incidence, response to
treatment or survival is yet to be determined.
The differences in the rates of BRAF mutation may reflect
differences in the underlying etiology of genomic instability
across these populations. BRAF mutations occur preferentially
in the ascending or proximal colon in precursor lesions referred
to as serrated adenomas. In the setting of BRAF mutation,
these adenomas generally progress to cancer through an
acquired DNA mismatch repair deficit caused by
hypermethylation of MLH1 in the setting of the CpG island
methylator phenotype (CIMP) [25]. Thus these tumors tend to
be characterized by microsatellite instability (MSI) and have
high rates of somatic mutations, especially small insertions and
deletions at small repeat regions. KRAS mutations, by contrast,
occur more often in colorectal cancers that harbor
chromosomal instability, the more common pattern of genomic
aberrations in sporadic colorectal cancer.
The lower rates of BRAF mutant colorectal cancer seen in
the Asian cohort could thus indicate that BRAF mutations
themselves may be less common in this group. Alternatively, it
is possible that there is a reduced propensity for pathologic
DNA hypermethylation in the Asian population studied, thus
reducing the ability of BRAF mutant precursor lesions to
progress towards cancer. We did not have sufficient genomic
material to pursue MSI testing or methylation testing for all
specimens, and thus we were not able to directly measure if
overall rates of CIMP-positive tumors were lower in the Asian
population. However, for 62 of 83 Asian cancers assayed for
MSI, only 3% (2/62) were MSI-high. This rate is lower than the
normally observed rate (10-15%) in sporadic colorectal
cancers, and consistent with a hypothesis that tumors driven by
these mechanisms may be less common in the Asian
population. Further work integrating more comprehensive
genomic information with MSI assays and methylation status
should clarify this.
The V600E mutation is an acquired activating mutation that
results in constitutively active BRAF kinase activity leading to
activation of the MAPK pathway. In melanoma, approximately
40% of patients have BRAF mutations of which 69% are
V600E. The V600E has also been found in benign nevi [26],
suggesting that V600 mutants may be early or precursor
events. Similarly, BRAF mutations have been found in
colorectal adenomas suggesting an early event in
tumorgenesis [27]. Ogino et al [28], looking at clinical trial
results (CALGB 89803) from 1264 stage III colorectal cancer
patients, clarified predictive and prognostic effects of BRAF
mutations and found BRAF mutants to be associated with
worse outcome. Although the frequency of BRAF mutations is
low (Asian, 4%; Black, 7%; White, 17%), compared to KRAS
(Asian, 39%; Black, 53%; White, 43%), BRAF may be an
important target for patients whose tumors harbor mutations.
Our finding of a lower mutation rate in our Asian cohort is of
interest. The Asian cohort is comprised of significantly more
lower stage patients and the cancers are predominantly distal
(Asian, 40%; Black, 25%; White, 21%) rather than proximal.
There does not appear to be an association between cancer
location and mutation rate. If we look at mutation rates by
Figure 2.  RAS/RAF family mutations by tumor and gene.  A summary chart of all RAS/RAF mutations in each patient group
displays genes across in rows and tumors down in columns. The bottom row of each represents the total number of mutations per
tumor as a heat map (0-5 mutations). Chart A displays Asian patients, chart B, Black patients and chart C, White patients.
doi: 10.1371/journal.pone.0074950.g002
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cancer location we find that in the Asian cohort 48% of patients
with distal cancers have no mutations compared to 19% of the
Black and 22% of the White cohort. Of the Asian patients with
distal cancers with mutations, there are 23 mutations in 17
patients (1.35 mutations per patient), less than either the Black
or White cohorts at 1.63 and 1.69 mutations per patient,
respectively. However, the average stage for distal, proximal
and rectal cancers is about the same. Moreover, while this
finding may truly represent a lower mutation rate for the Asian
cohort, it also may be that the spectrum of mutations in this
population is not well represented in OncoMap.
The rising incidence of colorectal cancer in many Asian
countries in the last few decades is marked [10,11,29] and
incidence in Korea has now surpassed the rate for Asian
Americans. Rates of mortality for Asian Americans, while
considerably lower than either Blacks or Whites, have been
steadily decreasing, likely due to the institution of screening as
a standard medical test. While the drivers behind this complex
picture are numerous, there is some evidence that shift from a
more traditional Asian diet to a Western style diet containing
more processed and red meats and alcohol [10,11], may be a
contributor.
The differences in the location of the cancers across our
cohorts are striking and significant with White patients having
more proximal cancers and Asians having more distal cancers.
It has been previously observed that distal cancers are more
common in the Korean [12] population and we observe this
difference in both our Korean cohort and our Asian American
cohort. Looking at tumor stage, we find all groups to have
stage III cancers most frequently but stage distribution is
otherwise diverse. There were more stage II cancers in the
Asian group and the fewest in the White group (Asian, 34%;
Black, 18%; White, 11%), and more stage IV cancers in the
White group and the least in the Asian (Asian, 5%; Black, 12%;
White, 19%). Looking at the average stage for each group, we
find Whites to have the highest average stage (Asian, 2.41;
Black, 2.85; White, 3.09).
KRAS mutations are well known in numerous cancers,
located most commonly at exon 2 amino acids G12 and G13,
two adjacent amino acids located near the catalytic site, and
have been shown to result in constitutive activation of the
MAPK signaling pathway. The prevalence of KRAS mutations
in the Black group is driven by the KRAS G12D, however, the
significance of KRAS G12D enrichment is unclear. This
observation has been previously reported by Sylvester et al
[19], however, they noted a higher frequency of G13 mutations
in colon cancers from Black patients compared to the White,
which we did not observe.
While there is some evidence that KRAS exon 2 mutations
may be associated with a worse prognosis [20], and that G13
mutations may result in a less aggressive cancer, the evidence
regarding the different effects of specific G12 or G13 variants is
sparse. There are a considerable number of possible
nucleotide changes at G12 and 13 resulting in different
mutations, and each of these may produce altered downstream
activity. A 2001 study by Andreyev et al [30] found that in
colorectal cancer, of all the codon 12 and 13 mutations, only
GGT to GTT transversions, resulting in G12V, were associated
with worse survival. In contrast, in pancreatic cancer, which
has the highest incidence of KRAS mutations of any cancer, 2
small studies [31,32] showed evidence that patients with G12V
(GTT) mutations have longer median survival and those with
G12D (GAT) have shorter. A recent and intriguing finding by
Garassino et al [33], showed in NSCLC cell lines, that the
G12D mutant had increased sensitivity to sorafenib (a MAP
Kinase pathway inhibitor) compared to G12V and G12C,
suggesting that differences at the nucleotide level may have
clinical implications.
However, Ogino et al [28], in looking at KRAS mutations in
the CALGB 89803 trial, found no significant effect on survival
or disease progression for KRAS mutant colorectal cancer
patients. Except for the predictive significance for efficacy of
anti-EGFR monoclonal antibodies in the setting of metastasis
for EGFR-expressing tumors [13], KRAS mutations appear to
have no effect on outcome.
Colorectal cancer is generally considered to progress from
adenoma to carcinoma, with APC and KRAS mutations
occurring early [34]; APC mutations in the normal epithelium
and KRAS somewhere along the transition from small to
medium size adenoma [34]. TP53 mutations are late events.
We have 7 patients each with more than 3 mutations (Figure
3), and when we look at these 7 samples, we can clearly see
evidence of the generally accepted pathway of colorectal
cancer progression: APC, as the first event, is found in 5/7;
KRAS, a later event, in 6/7; and TP53, the last step to a
carcinoma, is found in half of the samples.
We found the mutation rates of oncogenes to be at the
expected frequencies [16]; however in tumor suppressor
genes, our frequencies were considerably below what is
expected. This is a limitation of the OncoMap platform in that it
assays for known mutations and, while mutations in oncogenes
tend to occur in the same locations, mutations in tumor
suppressors occur more randomly across the gene. Next
generation sequencing will be able to overcome most of the
shortcomings inherent in OncoMap.
Figure 3.  Hyper-mutated samples.  Represented here are
the genes mutated in the 7 patient samples that each have four
or more mutations. A, W and B represent tumors from Asian,
Black or White tumors, respectively.
doi: 10.1371/journal.pone.0074950.g003
BRAF Mutations in Colorectal Cancer
PLOS ONE | www.plosone.org 8 September 2013 | Volume 8 | Issue 9 | e74950
Genomic variations not included in OncoMap may yet
explain some of the differences in our patient groups, for
example, mutations in regions not covered by OncoMap, copy
number or gene expression alterations, or epigenetic
alterations. Further research should focus on an expanded set
of genomic alterations, and integration of these data with MSI
testing and/or assessment of CIMP in carefully controlled
studies with extensive patient annotations where staging,
diagnosis and treatment are equal.
In summary, we have identified differences in the somatic
mutation frequency of known cancer genes in colorectal
cancers from Asian, Black and White patients. These data
argue in favor of using a genomics-driven precision medicine
approach in order to elucidate the different ancestral
determinants harbored by patient populations and thus, to
more precisely and effectively treat colorectal cancer.
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